The 2026 outlook is unchanged and broadly in line with expectations. Labcorp reaffirmed guidance last updated on July 30, rather than raising it again. 〔0〕 The adjusted EPS range of $18.10-$18.55 brackets the published consensus of roughly $18.32, putting the midpoint essentially on expectation.
| Metric | 2026 guidance | Comparison |
|---|---|---|
| Enterprise revenue | $14,710-$14,827 million | 5.4%-6.3% growth; 2025 revenue $13,952 million (Guidance table) |
| Diagnostics Laboratories revenue | $11,450-$11,532 million | 5.3%-6.0% growth; 2025 revenue $10,876 million (Guidance table) |
| Biopharma Laboratory Services revenue | $3,269-$3,300 million | 5.5%-6.5% growth; 2025 revenue $3,098 million (Guidance table) |
| Adjusted EPS | $18.10-$18.55 | Consensus approximately $18.32 |
| Free cash flow | $1,240-$1,360 million | No clean published benchmark provided |
The genuinely new information is the long-term framework, not a near-term reset. Through 2029, management expects revenue to compound at 5%-8% annually and adjusted EPS at 8.5%-11.5%, with 75-150 basis points of adjusted operating-margin expansion. 〔1〕 Those targets broadly extend the company's existing high-single-digit EPS-growth narrative rather than introducing a materially higher ambition.
The net read is confirmation, not a beat. The investor-day event was scheduled and the 2026 guidance had already been disclosed, so the filing mainly removes downside risk while giving investors a longer planning horizon. With no guidance increase and no clear evidence that the 2029 range exceeds the market's standing assumptions, the appropriate scorecard is reaffirmed guidance rather than positive surprise.
Read the original 8-K on SEC EDGAR ↗